x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAA-001289
| Product Information | |
|---|---|
| Product Name | Rat Retn/Resistin Antibody Pair - BSA and Azide free |
| Species | Rat |
| Description | Rat Retn Antibody Pair is a matched pair of unconjugated recombinant rabbit monoclonal capture and detection antibodies used to quantify Rat Retn in sandwich ELISAs and many other pair-based applications. |
| Detection Range | 31.25 pg/mL - 2000 pg/mL |
| Target Information | |
|---|---|
| Target Name | RETN |
| UniProt No. | Q9HD89 |
| Gene ID | 56729 |
| Target Description | Hormone that seems to suppress insulin ability to stimulate glucose uptake into adipose cells. Potentially links obesity to diabetes. |
| Alternative Names | Adipose tissue specific secretory factor; Adipose tissue-specific secretory factor; ADSF; C/EBP epsilon regulated myeloid specific secreted cysteine rich protein; C/EBP epsilon regulated myeloid specific secreted cysteine rich protein precursor 1; C/EBP-epsilon-regulated myeloid-specific secreted cysteine-rich protein; CG5403; Cysteine rich secreted protein A12 alpha like 2; Cysteine rich secreted protein FIZZ3; Cysteine-rich secreted protein A12-alpha-like 2; Cysteine-rich secreted protein FIZZ3; dri; FIZZ 3; FIZZ3; Found in inflammatory zone 3; HXCP 1; HXCP1; MGC126603; MGC126609; PRO1199; Resistin; Resistin delta2; RETN; RETN 1; RETN_HUMAN; RETN1; RSTN; UNQ407; XCP 1; XCP1 |
| Shipping & Storage | |
|---|---|
| Sipping | Shipping on dry ice. |
| Storage | Store at +4°C. Please refer to protocols. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
